Evidence map›Paper›PMID 28081538›Full record

Trial reportBritish journal of cancer2017

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.

Anna Kazarian, Oleg Blyuss, Gergana Metodieva, Aleksandra Gentry-Maharaj, Andy Ryan, Elena M Kiseleva, Olga M Prytomanova, Ian J Jacobs, Martin Widschwendter, Usha Menon and 1 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.

  1. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Anna KazarianDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
Oleg BlyussDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
Gergana MetodievaDepartment of Biological Sciences, University of Essex, Colchester, Essex CO4 3SQ, UK.
Aleksandra Gentry-MaharajDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
Andy RyanDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
Elena M KiselevaOles Honchar Dnipropetrovsk National University, Dnipropetrovsk, Ukraine.
Olga M PrytomanovaOles Honchar Dnipropetrovsk National University, Dnipropetrovsk, Ukraine.
Ian J JacobsUniversity of New South Wales, Sydney, NSW 2052, Australia.
Martin WidschwendterDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
Usha MenonDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
John F TimmsDepartment of Women's Cancer, Institute for Women's Health, University College London, London, W1T 7DN, UK.
University College London · GBOles Honchar Dnipro National University · UAUniversity of Essex · GBUNSW Sydney · AU

Funding

Medical Research Council G0801228Medical Research Council G9901012
6 · The paper itself

Abstract

backgroundBreast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of serological biomarkers in a case-control cohort of sera taken before diagnosis.

methodsThis nested case-control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-pathological features and between case controls in different time groups before diagnosis.

resultsSignificant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3, HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.

conclusionsThis study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for screening.

Indexed as

AgedBiomarkers, TumorBreast NeoplasmsCase-Control StudiesEarly Detection of CancerEnzyme-Linked Immunosorbent AssayFemaleHumansMass ScreeningMiddle AgedPrognosisUnited KingdomBiomarkers, Tumor

Identifiers

PMID28081538
PMCPMC5318971
OpenAlexW2579783581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.